SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Saat ini sedang diselidiki dalam uji coba penting Fase 2, CART-ddBCMA adalah terapi sel-T Arcellx yang memanfaatkan pengikat sintetis baru perusahaan, D-Domain. Kite dan Arcellx akan bersama-sama memajukan dan mengkomersialkan aset CART-ddBCMA di AS, dan Kite akan mengkomersialkan produk di luar AS
Terapi CAR T-Cell adalah salah satu pengobatan terobosan untuk beberapa jenis kanker darah. Ada lebih dari 750 yang sedang berlangsung uji klinis in Terapi CAR T-Cell di Cina saat sekarang. Pasien yang ingin mendaftar dapat menghubungi KankerFax saluran bantuan pasien di WhatsApp +91 96 1588 1588 atau email ke info@cancerfax.com.
Tentang Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory mieloma multipel (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk sindrom Myelodysplastic, initiated in the fourth quarter of 2022.
Tentang layang-layang
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Tentang Gilead Sciences
Gilead Sciences, Inc. adalah perusahaan biofarmasi yang telah mengejar dan mencapai terobosan di bidang kedokteran selama lebih dari tiga dekade, dengan tujuan menciptakan dunia yang lebih sehat bagi semua orang. Perusahaan berkomitmen untuk memajukan obat-obatan inovatif untuk mencegah dan mengobati penyakit yang mengancam jiwa, termasuk HIV, virus hepatitis, dan kanker. Gilead beroperasi di lebih dari 35 negara di seluruh dunia, dengan kantor pusat di Foster City, California. Gilead Sciences mengakuisisi Kite pada tahun 2017.
